S&P 500
7,485.80
-0.07%
Dow Jones
52,361.60
+0.01%
Nasdaq 100
29,699.60
-0.56%
Russell 2000
3,006.76
-0.21%
FTSE 100
10,462.80
-0.24%
Nikkei 225
68,537.30
-1.57%
Guardant Health

Guardant Health (GH) Q4 2025 Earnings

Reported Feb 19, 2026 at 4:12 PM ET · SEC Source

Q4 25 EPS

$-0.50

MISS 6.52%

Est. $-0.47

Q4 25 Revenue

$281.3M

BEAT +3.30%

Est. $272.3M

vs S&P Since Q4 25

+46.7%

BEATING MARKET

GH +54.9% vs S&P +8.2%

Full Year 2025 Results

FY 25 EPS

$-1.82

FY 25 Revenue

$982.0M

Market Reaction

Did GH Beat Earnings? Q4 2025 Results

Guardant Health closed out fiscal 2025 with a mixed fourth quarter, posting revenue of $281.27 million, a 39.4% year-over-year gain that cleared the $272.28 million consensus estimate by 3.30%, even as its loss per share of $0.50 fell short of the $0… Read more Guardant Health closed out fiscal 2025 with a mixed fourth quarter, posting revenue of $281.27 million, a 39.4% year-over-year gain that cleared the $272.28 million consensus estimate by 3.30%, even as its loss per share of $0.50 fell short of the $0.47 analyst forecast by 6.52%. The primary engine behind the revenue strength was the explosive ramp of Shield, the company's colorectal cancer screening blood test, which generated $35.13 million in the quarter versus just $4.12 million a year earlier as test volumes surged to roughly 38,000 from 6,400, a commercial acceleration underscored by a nationwide mobile screening tour aimed at broadening access in underserved communities. Oncology testing also contributed meaningfully, with Q4 revenue climbing 30% to $189.95 million on approximately 79,000 tests. Looking ahead, management guided 2026 total revenue of $1.25 billion to $1.28 billion, representing 27% to 30% growth, with Shield volume expected to roughly double to 210,000 to 225,000 tests and free cash flow burn narrowing to $185 million to $195 million from $233 million in 2025.

Key Takeaways

  • • Oncology test volume grew 38% year-over-year to approximately 79,000 tests in Q4
  • • Shield screening tests grew to approximately 38,000 from 6,400 in the prior year quarter
  • • Non-GAAP gross margin expanded to 66% from 63% in Q4 2024
  • • Commercial team expansion and marketing activities drove growth across Shield and existing products
24/7 Wall St

GH YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

24/7 Wall St

GH Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“We delivered an outstanding end to a great year, with fourth quarter revenue growth of 39% year-over-year. Our progress in 2025 is a testament to our breakthrough innovation and best-in-class execution across our portfolio. We are uniquely positioned with scaled offerings spanning both therapy selection and monitoring, and the recent launch of Reveal for therapy response monitoring further strengthens our competitive moat. We look forward to another strong year ahead, supported by a diverse set of growth catalysts across our business.”

— Helmy Eltoukhy, Q4 2025 Earnings Press Release

Back to GH Stock Page